Heart Failure: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

“GervanoRA’s pipeline analysis and opportunity assessment report “Heart Failure: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Heart Failure pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Heart Failure industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Unmet needs and Opportunities
• Epidemiology and Epidemiology forecast 2018 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Patent Analysis of Pipeline Molecules
• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.”

“TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. REPORT MAJOR FINDINGS
2.2. KEY EVENTS IN HEART FAILURE COMPETITIVE SPACE
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. HEART FAILURE PHASE 3 MOLECULES
5.1.2. HEART FAILURE PHASE 2 MOLECULES
5.1.3. HEART FAILURE PHASE 1 MOLECULES
5.1.4. HEART FAILURE PRECLINICAL MOLECULES
5.1.5. HEART FAILURE EARLY R&D MOLECULES
5.1.6. HEART FAILURE INACTIVE AND DISCONTINUED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
6. ESTIMATED APPROVAL TIMELINE
6.1.1. METHODOLOGY
6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
7. HEART FAILURE CLINICAL TRIALS SUMMARY
7.1. HEART FAILURE PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
7.1.1. KEY PHASE 3 RESULTS
7.1.2. KEY PHASE 2 RESULTS
7.2. ONGOING CLINICAL TRIALS SUMMARY
7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
7.3. PLANNED CLINICAL TRIALS SUMMARY
7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
8.1. COMPANIES
8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
8.1.2. TOP 20 EMERGING COMPANIES IN THE HEART FAILURE AREA
8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
9. ABBREVIATIONS
LIST OF TABLES:
TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE HEART FAILURE AREA
TABLE 04: MAJOR LICENSING AGREEMENTS IN THE HEART FAILURE AREA
TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE HEART FAILURE AREA
TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE HEART FAILURE AREA
TABLE 07: MAJOR FINANCING DEALS IN THE HEART FAILURE AREA
TABLE 08: MAJOR DEALS IN THE HEART FAILURE AREA RANKED BY DEAL AMOUNT
TABLE 09: US FDA APPROVED DRUGS SINCE 2010
TABLE 10: EX-US APPROVED DRUGS SINCE 2010
TABLE 11: PHASE 3 MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 12: PHASE 2 MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 13: PHASE 1 MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 14: PRECLINICAL MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 15: EARLY R&D MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE HEART FAILURE DRUG PIPELINE
TABLE 17: HEART FAILURE PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 18: HEART FAILURE PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 19: HEART FAILURE PIPELINE MOLECULES BY UNIVERSITIES
TABLE 20: HEART FAILURE PIPELINE MOLECULES BY INSTITUTES
TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 25: PLANNED CLINICAL TRIALS FOR THE HEART FAILURE AREA
TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 29: ESTABLISHED COMPANIES SCENARIO
TABLE 30: LIST OF EMERGING COMPANIES IN THE HEART FAILURE AREA
TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
(Above mentioned tables are a few among the total 91 tables in the report)
LIST OF FIGURES:
FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
FIGURE 02: HEART FAILURE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
FIGURE 03: OVERALL DEALS ACTIVITY IN THE HEART FAILURE AREA
FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 06: HEART FAILURE DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 07: HEART FAILURE DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 08: HEART FAILURE DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 09: HEART FAILURE DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10: HEART FAILURE DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 11: HEART FAILURE PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 15: COMPANY FINANCIAL INFORMATION
FIGURE 16: COMPANY SWOT ANALYSIS
(Above mentioned figures are a few among the total 49 figures in the report)”